EIC VentureMatch E‑pitch on Biotech and Pharma: who showed, who attended and what it means for scaling deep biotech

Brussels, August 3rd 2026

Summary

›The EIC VentureMatch E‑pitch on Biotech and Pharma ran online on 28 July 2026 and convened 43 participants including 8 EIC-backed companies and 27 investors.
›Organisers report more than 145 conversations and 33+ meetings on the matchmaking platform, with Asgard Therapeutics selected as the pitch winner.
›Pitched projects ranged from first-in-class cellular reprogramming and innate immune conditioners to AI‑driven drug discovery and mRNA manufacturing.
›The event illustrates the EIC Business Acceleration Services role in opening investor access for European deep tech, while early‑stage clinical and manufacturing risks remain significant.

EIC VentureMatch E‑pitch on Biotech and Pharma: bridging EIC awardees and sector investors

On 28 July 2026 the European Innovation Council's VentureMatch programme ran a sector‑focused online E‑pitch for biotech and pharma. The session is part of an ongoing effort by the EIC Business Acceleration Services to expose EIC‑backed innovators to pre‑vetted investors, corporates and procurers. Organisers report 43 participants in total, including eight pitching EIC awardees from four countries and 27 investors. The matchmaking platform logged more than 145 conversations and over 33 scheduled meetings linked to the activity.

Event format, audience and quantitative outcomes

Each company gave a three‑minute pitch followed by a four‑minute Q&A with jury members drawn from leading life‑science investors and corporate venture arms. The EIC summarised platform activity with counts of conversations and meetings. Those metrics measure engagement but should not be read as investment commitments. They are an early step in the long, asset‑by‑asset process investors need to complete before writing cheques.

Who attended on the investor side

The investor panel represented a typical cross‑section of the European life‑science venture community. Names explicitly cited by the EIC include Heal Capital, Industrifonden, Adbio Partners and Sanofi Ventures. Participants also included independent and regional VCs such as BiomedVC. According to jury feedback, the mix included operators with academic and translational science backgrounds as well as investors focused on biotech, immunology, vaccines and drug discovery technologies.

Why sector familiarity matters:Biotech and pharma investing depends heavily on domain knowledge. Investors familiar with mechanisms of action, regulatory timelines and manufacturing constraints are more likely to move beyond initial meetings. That explains why organisers curate investor lists for these pitches and why winning exposure is useful but not sufficient to secure financing.

The winning pitch: Asgard Therapeutics

Asgard Therapeutics, a Swedish private biotech, won the E‑pitch. The company develops in vivo direct cell reprogramming as a cancer immunotherapy. Its lead programme AT‑108 is described by the organisers as being in the IND‑enabling phase and presented as a first‑in‑class, off‑the‑shelf gene therapy that reprogrammes tumour cells into cDC1 dendritic cells to trigger personalised anti‑tumour immunity. The jury awarded exposure and a ticket to Bits & Pretzels in Munich as part of the prize.

In vivo direct cell reprogramming explained:Direct cell reprogramming means converting one differentiated cell type into another without reverting to a pluripotent stem cell state. In vivo approaches attempt that conversion inside the patient. For cancer immunotherapy the idea is to turn tumour cells into professional antigen‑presenting cells that can prime T cells locally. The approach is scientifically ambitious and carries translational hurdles including delivery, off‑target effects, regulatory complexity and manufacturing controls for gene‑therapy products.

Cristiana Pires of Asgard highlighted the access benefit of EIC pitching: even online sessions can accelerate introductions to investors who already understand the field. That endorsement speaks to the visibility value EIC channels provide for selected awardees. Still, investors will expect IND‑enabling data packages, scalable CMC strategies and clear clinical development plans before committing capital.

Who pitched: short dossiers of the eight EIC-backed companies

The E‑pitch showcased eight companies. Below are concise profiles summarising the technology claims reported by the EIC and publicly available company material. These are neutral descriptions and are not endorsements.

Company	Country	Core proposition / stage (as reported)
Asgard Therapeutics	Sweden	In vivo direct cell reprogramming for cancer immunotherapy. Lead AT‑108 in IND‑enabling phase; reprogrammes tumour cells into cDC1 dendritic cells.
bYoRNA	France	Cell‑based platform to design and manufacture low‑immunogenic mRNA using AI design and yeast‑based bioproduction.
EMUNO Therapeutics GmbH	Germany	Drugs to control immunity. Focus on target‑tailored discovery and optimisation strategies for immune modulation.
Exeliom Biosciences	France	EXL01, a first‑in‑class innate immune conditioner intended to restore myeloid support and extend checkpoint inhibitor durability. Multiple Phase 1/2a studies referenced.
HEPHAISTOS‑Pharma	France	Third‑generation TLR4 agonist engineered for higher safety and efficacy against tumour myeloid immunosuppression.
Iktos	France	Generative AI and robotics for drug discovery. Platform components include Makya (generative design), Spaya (retrosynthesis) and automated synthesis/DMTA workflows. Named as EIC Accelerator awardee in public company material.
NaDeNo	Norway	Medicinal nanotechnology spin‑off from SINTEF targeting intraperitoneal micro‑metastases in ovarian cancer via local drug delivery platforms.
O11 biomedical GmbH	Germany	Developing a first‑in‑class drug for chronic obstructive pulmonary disease. Produces RESPILIQ in its own GMP pilot plant.

Selected technology explainers

cDC1 dendritic cells:Conventional dendritic cells subtype 1 are professional antigen‑presenting cells particularly efficient at cross‑presenting tumour antigens to CD8+ T cells. Therapies that increase cDC1 presence or function in tumours aim to boost the initial phases of anti‑tumour immunity.

TLR4 agonists and myeloid reprogramming:Toll‑like receptor 4 agonists activate innate immune signalling and can reprogramme myeloid cells. Past generations of TLR4 agonists showed promise but also raised safety questions. Companies now emphasise rational design to separate desirable immune activation from systemic toxicity.

Generative AI with robotics in drug discovery:Combining AI for molecular design with automated synthesis and testing shortens the DMTA cycle. The approach can accelerate hit discovery and lead optimisation but integration of predictive models, high‑quality biological data and robust automation workflows remains technically demanding.

Why these meetings matter and what to watch next

The EIC VentureMatch events are designed to surface curated deal flow to investors who may already be familiar with the scientific area. For EIC awardees the immediate benefits are visibility, investor feedback and introductions. For the ecosystem the event showcases how public innovation programmes can act as a pipeline feeder.

A note of caution is warranted. Early‑stage biotech signals and short pitch metrics are only early engagement indicators. Institutional investors will still insist on reproducible preclinical data, manufacturability and a credible regulatory and clinical path before financing. For therapeutics, clinical development timelines, safety hurdles and scale‑up are the usual gating factors.

The EIC VentureMatch programme and EIC Business Acceleration Services in context

The VentureMatch programme is part of the EIC Business Acceleration Services. Its stated remit is investor readiness and matchmaking for EIC beneficiaries across Pathfinder, Transition, Accelerator and STEP Scale Up. The EIC reports hundreds of prior introductions and a reported +98% satisfaction rate in some activities. The broader BAS offering includes coaching, corporate partnering programmes, innovation procurement support and access to the EIC Service Catalogue.

Why public matchmaking helps but does not replace private diligence:Public programmes reduce search friction and lower the visibility barrier for startups. They create an early filtering mechanism. However, private investors perform independent technical, commercial and regulatory due diligence and use the programme output only as a starting point.

Practical takeaways for founders and investors

For founders: use EIC platforms to get in front of active sector investors but build the evidence package investors need. That includes IND‑enabling package planning, validated manufacturing routes for biologics or cell‑based products, and realistic timelines for clinical readouts. For platform and AI companies, demonstrate integration between in silico design and wet‑lab validation with reproducible datasets.

For investors and corporate partners: the EIC provides curated deal flow that is useful for sourcing. Expect to transform initial conversations into multi‑stage diligence processes. Pay particular attention to CMC plans and regulatory strategy for gene therapies, cell reprogramming and live biotherapeutics, and to data provenance for AI‑driven discovery platforms.

How to follow up

Investors interested in the companies that pitched can contact them via the Dealroom matchmaking platform used by the EIC. Companies and investors with questions about the VentureMatch programme are invited to contact the EIC Community contact page with the subject 'EIC VentureMatch Programme'. The EIC also publishes newsletters and maintains the EIC Community platform and the EIC Service Catalogue for follow‑on opportunities.

Final assessment

The event illustrates the pragmatic role European public innovation programmes can play in lowering discovery friction between science and capital. The headline metrics show activity and interest. What remains is the hard work that always follows such matches: rigorous technical validation, scaled manufacturing, regulatory approvals and long clinical paths. These are where value is created and where many projects will encounter the greatest hurdles.